SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cytrx Corp – ‘10-K’ for 12/31/11 – ‘EX-3.1’

On:  Tuesday, 3/13/12, at 8:27am ET   ·   For:  12/31/11   ·   Accession #:  799698-12-9   ·   File #:  0-15327

Previous ‘10-K’:  ‘10-K’ on 3/11/11 for 12/31/10   ·   Next:  ‘10-K’ on 3/11/13 for 12/31/12   ·   Latest:  ‘10-K’ on 3/27/24 for 12/31/23   ·   13 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/13/12  Cytrx Corp                        10-K       12/31/11   50:5.7M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Form 10-K for Year Ended December 31, 2011          HTML   1.20M 
 2: EX-3.1      Amended and Restated Certificate of Incorporation   HTML     61K 
                of Cytrx Corporation, as Amended                                 
 4: EX-10.12    Third Amendment to Third Amended and Restated       HTML     18K 
                Employment Agreement, Dated January 1, 2012,                     
                Between Cytrx Corporation and Steven A. Kriegsman                
 5: EX-10.20    Employment Agreement Dated January 1, 2012 Between  HTML     72K 
                Cytrx Corporation and Daniel Levitt, M.D., Ph.D.                 
 6: EX-10.21    Employment Agreement Dated January 1, 2012,         HTML     59K 
                Between Cytrx Corporation and Scott Geyer                        
 7: EX-10.22    Employment Agreement Dated January 1, 2012,         HTML     61K 
                Between Cytrx Corporation and Benjamin S. Levin                  
 8: EX-10.23    Employment Agreement Dated January 1, 2012,         HTML     61K 
                Between Cytrx Corporation and Scott Wieland                      
 9: EX-10.24    Employment Agreement Dated January 1, 2012,         HTML     60K 
                Between Cytrx Corporation and John Y. Caloz                      
10: EX-10.26    Investment Banking Agreement Dated February 14,     HTML     58K 
                2012, Between Cytrx Corporation and Legend                       
                Securities, Inc.                                                 
 3: EX-10.6     Cytrx Corporation Amended and Restated 2008 Stock   HTML     87K 
                Incentive Plan                                                   
11: EX-23.1     Consent of Bdo Usa, LLP                             HTML     17K 
12: EX-31.1     Certification -- §302 - SOA'02                      HTML     22K 
13: EX-31.2     Certification -- §302 - SOA'02                      HTML     22K 
14: EX-32.1     Certification -- §906 - SOA'02                      HTML     18K 
15: EX-32.2     Certification -- §906 - SOA'02                      HTML     18K 
34: R1          Document And Entity Information                     HTML     44K 
27: R2          Consolidated Balance Sheets                         HTML    118K 
32: R3          Consolidated Balance Sheets (Parenthetical)         HTML     45K 
36: R4          Consolidated Statements of Operations               HTML     78K 
47: R5          Consolidated Statements of Stockholders' Equity     HTML     73K 
28: R6          Consolidated Statements of Cash Flows               HTML    142K 
31: R7          Nature of Business                                  HTML     23K 
26: R8          Summary of Significant Accounting Policies          HTML     73K 
24: R9          Recent Accounting Pronouncements                    HTML     24K 
48: R10         Receivable                                          HTML     19K 
38: R11         Prepaid and Other Assets                            HTML     18K 
37: R12         Marketable securities                               HTML     21K 
42: R13         Equipment and Furnishings                           HTML     28K 
43: R14         Accrued Expenses and Other Current Liabilities      HTML     29K 
41: R15         Warrant Liabilities                                 HTML     18K 
44: R16         Commitments and Contingencies                       HTML     50K 
33: R17         Equity Transactions                                 HTML     31K 
35: R18         Investments in RXi and ADVENTRX Pharmaceuticals     HTML     24K 
40: R19         Stock Options and Warrants                          HTML    254K 
50: R20         Sale of Assets                                      HTML     19K 
45: R21         ALSCRT Amendment                                    HTML     18K 
29: R22         Stockholder Protection Rights Plan                  HTML     21K 
39: R23         Income Taxes                                        HTML     62K 
30: R24         Quarterly Financial Data (Unaudited)                HTML     55K 
23: R25         Subsequent Events                                   HTML     20K 
46: R26         Schedule II Valuation and Qualifying Accounts       HTML     38K 
49: XML         IDEA XML File -- Filing Summary                      XML     54K 
25: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    565K 
16: EX-101.INS  XBRL Instance -- cytr-20111231                       XML    784K 
18: EX-101.CAL  XBRL Calculations -- cytr-20111231_cal               XML    120K 
19: EX-101.DEF  XBRL Definitions -- cytr-20111231_def                XML     76K 
20: EX-101.LAB  XBRL Labels -- cytr-20111231_lab                     XML    498K 
21: EX-101.PRE  XBRL Presentations -- cytr-20111231_pre              XML    273K 
17: EX-101.SCH  XBRL Schema -- cytr-20111231                         XSD     60K 
22: ZIP         XBRL Zipped Folder -- 0000799698-12-000009-xbrl      Zip     70K 


‘EX-3.1’   —   Amended and Restated Certificate of Incorporation of Cytrx Corporation, as Amended


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C:   C: 
 
EXHIBIT 3.1
RESTATED CERTIFICATE OF INCORPORATION OF
 
CYTRX CORPORATION
 
As Approved by the Board of Directors on November 13, 2007
 
CytRx Corporation, a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows:
 
1.           The name of the corporation is CytRx Corporation. CytRx Corporation was originally incorporated under the name SynthRx, Inc., and the original certificate of incorporation of the corporation was filed with the Secretary of State of Delaware on February 28, 1985.
 
2.           This Restated Certificate of Incorporation was duly adopted in accordance with Section 245 of the Delaware General Corporation Law.
 
3.           This Restated Certificate of Incorporation merely restates and integrates, but does not further amend, the provisions of the corporation’s certificate of incorporation as theretofore amended or supplemented, and there is no discrepancy between those provisions and the provisions of this Restated Certificate of Incorporation.
 
SECOND.  The name of the corporation (hereinafter called the “corporation”) is CytRx Corporation.
 
THIRD.  The address, including street, number, city, and county, of the registered office of the corporation in the State of Delaware is 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle; and the name of the registered agent of the corporation in the State of Delaware at such address is The Prentice-Hall Corporation System, Inc.
 
FOURTH.  The nature of the business and of the purposes to be conducted and promoted by the corporation are as follows:
 
To manufacture, prepare, compound, refine, distill, produce, invent, discover, devise, develop, conduct scientific researches in respect of and exploit the findings therefrom, acquire, assign, and transfer formulae, concentrates, compounds, and processes for, apply, buy, sell, import and export, and generally deal in and with at wholesale and retail and as principal, agent, broker, distributor, sales, financial, and special representative, licensor, licensee, and in any other lawful capacity, pharmaceuticals, drugs and nutritional aspects for animals and humans.
 
To engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.
 
FIFTH.  The total number of shares of all classes of stock that the corporation shall have the authority to issue is One Hundred Fifty-Five Million (155,000,000), of which One Hundred Fifty Million (150,000,000) shall be common stock, par value $.001 per share (the“Common Stock”), and Five Million (5,000,000) shall be preferred stock, par value $.01 per share (the “Preferred Stock”).
 

 
 

 

The Board of Directors is hereby authorized, subject to any limitations prescribed by law, to provide for the issuance of the shares of Preferred Stock in series, and by filing a Certificate pursuant to the applicable law of the State of Delaware (hereinafter referred to as a “Preferred Stock Designation”), to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, and rights of the shares of each such series, any qualifications, limitations or restrictions thereof.
 
1.           Series A Junior Participating Preferred Stock. There is hereby established a series of Preferred Stock, par value $0.01 per share, of the Corporation, and the designation and certain terms, powers, preferences and other rights of the shares of such series, and certain qualifications, limitations and restrictions thereon, are hereby fixed as follows:
 
(i)           The distinctive serial designation of this series shall be “Series A Junior Participating Preferred Stock” (hereinafter called “this Series”). Each share of this Series shall be identical in all with the other shares of this Series except as to the date from and after which dividends thereon shall be cumulative.
 
(ii)           The number of shares in this Series shall be 5,000, which number may from time to time be increased or decreased (but not below the number then outstanding) by the Board of Directors. Shares of this Series purchased by the Corporation shall be canceled and shall revert to authorized but unissued shares of Preferred Stock undesignated as to series. Shares of this Series may be issued in fractional shares, which fractional shares shall entitle the holder, in proportion to such holder’s fractional share, to all rights of a holder of a whole share of this Series.
 
(iii)           The holders of full or fractional shares of this Series shall be entitled to receive, when and as declared by the Board of Directors, but only out of funds legally available therefor, dividends, (A) on each date that dividends or other distributions payable in Common Stock of the Corporation are payable on or in respect of Common Stock comprising part of the Reference Package (as defined below), in an amount per whole share of this Series equal to the aggregate amount of dividends or other distributions (other than dividends or distributions payable in Common Stock of the Corporation) that would be payable on such date to a holder of the Reference Package and (B) on the last day of March, June, September and December in each year, in an amount per whole share of this Series equal to the excess (if any) of $1.00 over the aggregate dividends paid per whole share of this Series during the three-month period ending on such last day. Each such dividend shall be paid to the holders of record of shares of this Series on the date, not exceeding sixty days preceding such dividend or distribution payment date, fixed for that purpose by the Board of Directors in advance of payment of each particular dividend or distribution. Dividends on each full and each fractional share of this Series shall be cumulative from the date such full or fractional share is originally issued; provided that any such full or fractional share originally issued after a dividend record date and on or prior to the dividend payment date to which such record date relates shall not be entitled to receive the dividend payable on such dividend payment date or any amount in respect of the period from such original issuance to such dividend payment date.
 

 
 

 

The term “Reference Package” shall initially mean 10,000 shares of Common Stock, par value $.00l per share (“Common Stock”), of the Corporation. In the event the Corporation shall at any time (A) declare or pay a dividend on any Common Stock payable in Common Stock, (B) subdivide any common Stock or (C) combine any Common Stock into a smaller number of shares, then and in each such case the Reference Package after such event shall be the Common Stock that a holder of the Reference Package immediately prior to such event would hold thereafter as a result thereof.
 
Holders of shares of this Series shall not be entitled to any dividends, whether payable in cash, property or stock, in excess of full cumulative dividends, as herein provided on this Series.
 
So long as any shares of this Series are outstanding, no dividend (other than a dividend in Common Stock or in any other stock ranking junior to this Series as to dividends and upon liquidation) shall be declared or paid or set aside for payment or other distribution declared or made upon the Common Stock or upon any other stock ranking junior to this Series as to dividends or upon liquidation, nor shall any Common Stock nor any other stock of the Corporation ranking junior to or on a parity with this Series as to dividends or upon liquidation be redeemed, purchased or otherwise acquired for any consideration (or any moneys be paid to or made available for a sinking fund for the redemption of any shares of any such stock) by the Corporation (except by conversion into or exchange for stock of the Corporation ranking junior to this series as to dividends and upon liquidation), unless, in each case, the full cumulative dividends (including the dividend to be due upon payment of such dividend, distribution, redemption, purchase or other acquisition) on all outstanding shares of this Series shall have been, or shall contemporaneously be, paid.
 
(iv)           In the event of any merger, consolidation, reclassification or other transaction in which the shares of Common Stock are exchanged for or changed into other stock or securities, cash and/or any other property, then in any such case the shares of this Series shall at the same time be similarly exchanged or changed in an amount per whole share equal to the aggregate amount of stock, securities, cash and/or any other property (payable in kind), as the case may be, that a holder of the Reference Package would be entitled to receive as a result of such transaction.
 
(v)           In the event of any liquidation, dissolution or winding up of the affairs of the Corporation, whether voluntary or involuntary, the holders of full and fractional shares of this Series shall be entitled, before any distribution or payment is made on any date to the holders of the Common Stock or any other stock of the Corporation ranking junior to this Series upon liquidation, to be paid in full an amount per whole share of this Series equal to-the greater of (A) $1.00 or (B) the aggregate amount distributed or to be distributed prior to such date in connection with such liquidation, dissolution or winding up to a holder of the Reference Package (such greater amount being hereinafter referred to as the “Liquidation Preference”), together with accrued dividends to such distribution or payment date, whether or not earned or declared. If such payment shall have been made in full to all holders of shares of this Series, the holders of shares of this Series as such shall have no right or claim to any of the remaining assets of the Corporation.
 

 
 

 

In the event the assets of the Corporation available for distribution to the holders of shares of this Series upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, shall be insufficient to pay in full all amounts to which such holders are entitled pursuant to the first paragraph of this Section (v), no such distribution shall be made on account of any shares of any other class or series of Preferred Stock ranking on a parity with the shares of this Series upon such liquidation, dissolution or winding up unless proportionate distributive amounts shall be paid on account of the shares of this Series, ratably in proportion to the full distributable, amounts for which holders of all such parity shares are respectively entitled upon such liquidation, dissolution or winding up.
 
Upon the liquidation, dissolution or winding up of the Corporation, the holders of shares of this Series then outstanding shall be entitled to be paid out of assets of the Corporation available for distribution to its stockholders all amounts to which such holders are entitled pursuant to the first paragraph of this Section (v) before any payment shall be made to the holders of Common Stock or any other stock of the Corporation ranking junior upon liquidation to this Series.
 
For the purposes of this Section (v), the consolidation or merger of. or binding share exchange by, the Corporation with any other corporation shall not be deemed to constitute a liquidation, dissolution or winding up of the corporation.
 
(vi)           The shares of this series shall not be redeemable.
 
(vii)           In addition to any other vote or consent of stockholders required by law or by the Certificate of Incorporation, as amended, of the Corporation, each whole share of this Series shall, on any matter, vote as a class with any other capital stock comprising part of the Reference Package and voting on such matter and shall have the number of votes thereon that a holder of the Reference Package would have.
 
SIXTH.  The name and the mailing address of the incorporator are as follows:
 
Name
 
Mailing Address
R.G. Dickerson
 
229 South State Street, Dover, Delaware

SEVENTH.  The corporation is to have perpetual existence.
 
EIGHTH.  Whenever a compromise or arrangement is proposed between this corporation and its creditors or any class of them and/or between this corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed, for this corporation under the provisions of section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for this corporation under the provisions of section 279 of Title 8 of the Delaware Code order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this corporation as consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of this corporation, as the case may be, and also on this corporation.
 

 
 

 

 
NINTH.  For the management of the business and for the conduct of the affairs of the corporation, and in further definition, limitation and regulation of the powers of the corporation and of its directors and of its stockholders or any class thereof, as the case may be, it is further provided:
 
1.           The management of the business and the conduct of the affairs of the corporation shall be vested in its Board of Directors. The number of directors which shall constitute the whole Board of Directors shall be fixed by, or in the manner provided in, the By-Laws. The phrase “whole Board” and the phrase “total number of directors” shall be deemed to have the same meaning, to wit, the total number of directors which the corporation would have if there were no vacancies. No election of directors need be by written ballot.
 
2.           After the original or other By-Laws of the corporation have been adopted, amended, or repealed, as the case may be, in accordance with the provisions of Section 109 of the General Corporation Law of the State of Delaware, and, after the corporation has received any payment for any of its stock, the power to adopt, amend, or repeal the By-Laws of the corporation may be exercised by the Board of Directors of the corporation; provided, however, that any provision for the classification of directors of the corporation for staggered terms pursuant to the provisions of subsection (d) of Section 141 of the General Corporation Law of the State of Delaware shall be set forth in an initial By-Law or in a By-Law adopted by the stockholders entitled to vote of the corporation unless provisions for such classification shall be set forth in this certificate of incorporation.
 
3.           Whenever the corporation shall be authorized to issue only one class of stock, each outstanding share shall entitle the holder thereof to notice of and the right to vote at, any meeting of stockholders. Whenever the corporation shall be authorized to issue more than one class of stock, no outstanding share of any class of stock which is denied voting power under the provisions of the certificate of incorporation shall entitle the holder thereof to the right to vote at any meeting of stockholders except as the provisions of paragraph (b) (2) of section 242 of the General Corporation Law of the State of Delaware shall otherwise require; provided, that no share of any such class which is otherwise denied voting power shall entitle the holder thereof to vote upon the increase or decrease in the number of authorized shares of said class.
 
TENTH.  The corporation shall, to the fullest extent permitted by Section 145 of the General Corporation Law of the State of Delaware, as the same may be amended and supplemented, indemnify any and all persons whom it shall have power to indemnify under said section from and against any and all of the expenses, liabilities or other matters referred to in or covered by said section, and the indemnification provided for herein shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any By-Law, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.
 

 
 

 


 
ELEVENTH.  From time to time any of the provisions of this certificate of incorporation may be amended, altered or repealed, and other provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted in the manner and at the time prescribed by said laws, and all rights at any time conferred upon the stockholders of the corporation by this certificate of incorporation are granted subject to the provisions of this Article TENTH.
 
TWELFTH.  A director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the Delaware General Corporation Law, or (iv) for any transaction from which the director derived any improper personal benefit. If the Delaware General Corporation Law is amended after approval by the stockholders of this Article to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law as so amended.
 
Any repeal or modification of the foregoing paragraph by the stockholders of the corporation shall not adversely affect any right or protection of a director of the corporation existing at the time of such repeal or modification.
 
IN WITNESS WHEREOF, this Restated Certificate of Incorporation has been signed by Steven A. Kriegsman, its authorized officer this 15th day of November 2007.
 

 
CYTRX CORPORATION
 
 
By:  /s/ Steven A. Kriegsman                                                         
Title:  President and Chief Executive Officer



 
 

 

CERTIFICATE OF INCREASE
 
OF
 
SHARES DESIGNATED
 
AS
 
SERIES A JUNIOR PARTICIPATING PREFERRED STOCK
 
* * * * *
 
CytRx Corporation, a corporation organized and existing under the General Corporation Law of the State of Delaware,
 
DOES HEREBY CERTIFY:
 
That an Amended and Restated Certificate of Incorporation of said corporation was filed in the Office of the Secretary of State of Delaware on November 15, 2007.
 
That the Board of Directors of said corporation duly adopted a resolution authorizing and directing an increase in the number of shares designated as Series A Junior Participating Preferred Stock of said corporation from 5,000 shares to 15,000 shares, in accordance with the provisions of section 151 of The General Corporation Law of the State of Delaware.
 
IN WITNESS WHEREOF, said CytRx Corporation has caused this certificate to be signed by Steven A. Kriegsman, its President and Chief Executive Officer this 24th day of January 2008.
 

 
CYTRX CORPORATION
 
 
By:  /s/ Steven A. Kriegsman                                                         
Title: President and Chief Executive Officer

 
 

 

CERTIFICATE OF AMENDMENT
 
TO
 
RESTATED CERTIFICATE OF INCORPORATION
 
OF CYTRX CORPORATION
 
CytRx Corporation, a Delaware corporation (the “Company”), hereby certifies that:
 
1.           The following resolution has been unanimously adopted by the Company’s Board of Directors and has been approved by the holders of a majority of the Company’s outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Company’s Restated Certificate of Incorporation:
 
RESOLVED, that the Restated Certificate of Incorporation of the Corporation be amended by deleting in its entirety the Fourth Article and by replacing it with the following:
 
“FOURTH: The total number of shares of all classes of stock that the corporation shall have the authority to issue is One Hundred Eighty Million (180,000,000), of which One Hundred Seventy Five Million (175,000,000) shall be common stock, par value $.001 per share (the “Common Stock”), and Five Million (5,000,000) shall be preferred stock, par value $.01 per share (the “Preferred Stock”).
 
The Board of Directors is hereby authorized, subject to any limitations prescribed by law, to provide for the issuance of the shares of Preferred Stock in series, and by filing a Certificate pursuant to the applicable law of the State of Delaware (hereinafter referred to as a “Preferred Stock Designation”), to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, and rights of the shares of each such series, any qualifications, limitations or restrictions thereof.”
 
2.           The above amendment was duly adopted by the Company in accordance with the provisions of Section 242 of the Delaware General Corporation Law.
 
IN WITNESS WHEREOF, CytRx Corporation has caused this Certificate of Amendment to be signed by a duly authorized officer on this 2nd day of July, 2008.
 

 
CYTRX CORPORATION
 
 
By:  /s/ Steven A. Kriegsman                                                         
Title: President and Chief Executive Officer

 
 

 

CERTIFICATE OF AMENDMENT
 
TO
 
RESTATED CERTIFICATE OF INCORPORATION OF
 
CYTRX CORPORATION
 
CytRx Corporation, a Delaware corporation (the “Company”), hereby certifies that:
 
1.           The following resolution has been unanimously adopted by the Company’s Board of Directors and has been approved by the holders of a majority of the Company’s outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Company’s Restated Certificate of Incorporation:
 
RESOLVED, that the Restated Certificate of Incorporation of the Company be amended by deleting in its entirety the Fourth Article and by replacing it with the following:
 
“FOURTH: The total number of shares of all classes of stock that the Company shall have the authority to issue is Two Hundred Fifty-Five Million (255,000,000), of which Two Hundred Fifty Million (250,000,000) shall be common stock, par value $.001 per share (the “Common Stock”), and Five Million (5,000,000) shall be preferred stock, par value $.01 per share (the “Preferred Stock”).
 
The Board of Directors is hereby authorized, subject to any limitations prescribed by law, to provide for the issuance of the shares of Preferred Stock in series, and by filing a Certificate pursuant to the applicable law of the State of Delaware (hereinafter referred to as a “Preferred Stock Designation”), to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, and rights of the shares of each such series, any qualifications, limitations or restrictions thereof.”
 
2.           The above amendment was duly adopted by the Company in accordance with the provisions of Section 242 of the Delaware General Corporation Law.
 
IN WITNESS WHEREOF, CytRx Corporation has caused this Certificate of Amendment to be signed by a duly authorized officer this 8th day of July 2011.
 

 
CYTRX CORPORATION
 
 
By:  /s/ John Y. Caloz                                                         
Title: Chief Financial Officer


 
 

 

CERTIFICATE OF INCREASE
 
OF
 
SHARES DESIGNATED
 
AS
 
SERIES A JUNIOR PARTICIPATING PREFERRED STOCK
 
CytRx Corporation, a corporation organized and existing under the General Corporation Law of the State of Delaware,
 
DOES HEREBY CERTIFY:
 
That an Amended and Restated Certificate of Incorporation of said corporation was filed in the Office of the Secretary of State of Delaware on November 15, 2007.
 
That the Board of Directors of said corporation duly adopted a resolution authorizing and directing an increase in the number of shares designated as Series A Junior Participating Preferred Stock of said corporation from 15,000 shares to 25,000 shares, in accordance with the provisions of section 151 of The General Corporation Law of the State of Delaware.
 
IN WITNESS WHEREOF, said CytRx Corporation has caused this certificate to be signed by a duly authorized officer this 8th day of July 2011.
 

 
CYTRX CORPORATION
 
 
By:  /s/ John Y. Caloz                                                         
Title: Chief Financial Officer


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/13/128-K
For Period end:12/31/11
11/15/07
11/13/078-K,  NT 10-Q
 List all Filings 


13 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/27/24  LadRx Corp.                       10-K       12/31/23   67:19M                                    M2 Compliance LLC/FA
 4/14/23  LadRx Corp.                       S-1                   66:6M                                     M2 Compliance LLC/FA
 3/20/23  LadRx Corp.                       10-K       12/31/22   72:6.2M                                   M2 Compliance LLC/FA
 3/23/22  LadRx Corp.                       S-1/A                  3:458K                                   M2 Compliance LLC/FA
 3/23/22  LadRx Corp.                       10-K       12/31/21   72:5.8M                                   M2 Compliance LLC/FA
11/12/21  LadRx Corp.                       10-Q        9/30/21   45:3.2M                                   M2 Compliance LLC/FA
 8/12/21  LadRx Corp.                       10-Q        6/30/21   43:2.8M                                   M2 Compliance LLC/FA
 8/04/21  LadRx Corp.                       S-1                    3:453K                                   M2 Compliance LLC/FA
 7/13/21  LadRx Corp.                       10-K/A     12/31/20    4:270K                                   M2 Compliance LLC/FA
 5/14/21  LadRx Corp.                       S-3/A                  3:316K                                   M2 Compliance LLC/FA
 4/22/21  LadRx Corp.                       S-3                    2:280K                                   M2 Compliance LLC/FA
 3/24/21  LadRx Corp.                       10-K       12/31/20   68:8.1M                                   M2 Compliance LLC/FA
10/23/20  LadRx Corp.                       S-8        10/23/20    5:265K                                   M2 Compliance LLC/FA
Top
Filing Submission 0000799698-12-000009   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 3:44:22.3am ET